Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme
Overall, our study provides valuable insights into the role of CLDN9 in various tumors and lays a foundation for more precise and individualized immunotherapy approaches for GBM in the future.
Authors
- Fang Peng (ORCID: https://orcid.org/0000-0002-4660-194X)
- Ning Li (ORCID: https://orcid.org/0009-0001-7242-9805)
- Yuanyuan Zhu
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1186/s12935-025-03852-5
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province